Literature DB >> 24597

Comparative potency of intravenous penbutolol and propranolol in man.

P L Sharma, R P Sapru.   

Abstract

A study on the comparative potency of intravenously administered penbutolol, a new non-selective beta adrenoceptor antagonist, on the resting and post-exercise heart rate and rate-pressure product was carried out in 5 normal human subjects. The effects produced by 0.1, 0.2 and 0.3 mg of penbutolol and of 0.025 mg/kg (mean dose 1.28 mg) of propranolol was recorded. The dose of penbutolol producing an effect equivalent to that of propranolol was calculating from the log dose-response curve of penbutolol. In these tests, penbutolol was 7.90 and 7.66 times more potent than propranolol on a weight to weight basis. Penbutolol was well tolerated and no side-effects were observed.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 24597

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Biopharm        ISSN: 0340-0026


  4 in total

1.  Penbutolol (Hoe 893d) in primary hypertension. Blood pressure effects, tolerance and plasma concentrations.

Authors:  K P Ohman; J Asplund; S Landahl; B Liander
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

2.  The effect on myocardial contractility of a new beta-adrenergic receptor blocking drug, penbutolol.

Authors:  R P Sapru; P L Sharma
Journal:  Br J Clin Pharmacol       Date:  1978-12       Impact factor: 4.335

3.  Penbutolol: a preliminary review of its pharmacological properties and therapeutic efficacy in hypertension and angina pectoris.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1981-07       Impact factor: 9.546

4.  Studies on the stereoisomers of beta-adrenoceptor antagonists in conscious A-V blocked dogs.

Authors:  M Boucher; P Duchêne-Marullaz; J L Moundanga
Journal:  Br J Pharmacol       Date:  1986-09       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.